Zafgen sinks after ending beloranib program

Zafgen Inc. (NASDAQ:ZFGN) fell $3.51 (52%) to $3.24 on Wednesday after saying late Tuesday that it will discontinue development of subcutaneous beloranib (ZFN-440). Zafgen was studying the candidate to treat Prader-Willi syndrome and severe obesity (see BioCentury Extra, July 19). ...